Forgot Password
To reset your password, submit your username or your email address below. If we can find you in the database, an email will be sent to your email address, with instructions on how to get access again.
Indication
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).
- TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.
Indication
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).
- TAUVID for intravenous use is supplied in multidose vials containing 300 MBq/mL to 3700 MBq/mL flortaucipir F 18.
Important Safety Information
Risk of Misdiagnosis in Patients Evaluated for Alzheimer's disease (AD)
TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD. TAUVID performance
for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level neurofibrillary tangle (NFT) pathology. TAUVID performance for detecting tau pathology may be lower in patients in earlier
stages of the pathological spectrum.
Negative TAUVID Scan
NFTs may be present at levels that qualify for the neuropathological diagnosis of AD (B2 tau pathology in the presence of at least moderate levels of cortical amyloid pathology) in patients
with a negative TAUVID scan. Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.
False Positive TAUVID Scan
Small foci of noncontiguous tracer uptake may lead to a false positive TAUVID scan. Only uptake of tracer in the neocortex should contribute to the interpretation
of a positive TAUVID scan.
Risk of Chronic Traumatic Encephalopathy Misdiagnosis
The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Preliminary non-clinical and clinical investigations
suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding. Therefore, TAUVID is not indicated for detection of CTE.
Radiation Risk
Diagnostic radiopharmaceuticals, including TAUVID, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer.
Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
ADVERSE REACTIONS
The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).
USE IN SPECIFIC POPULATIONSPregnancyAll radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development
and the magnitude radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.
LactationAdvise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant.
Please see Full Prescribing Information for TAUVID.
FT HCP ISI 14SEP2022
Indication
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).
- TAUVID for intravenous use is supplied in multidose vials containing 300-3700 Mbq/mL flortaucipir F 18.
Important Safety Information
Risk of Misdiagnosis in Patients Evaluated for Alzheimer's disease (AD)
TAUVID does not target β-amyloid, one of two required components of the neuropathological diagnosis of AD. TAUVID performance
for detecting tau pathology was assessed in terminally ill patients, the majority of whom had AD dementia with B3 level neurofibrillary tangle (NFT) pathology. TAUVID performance for detecting tau pathology may be lower in patients in earlier
stages of the pathological spectrum.
Negative TAUVID Scan
NFTs may be present at levels that qualify for the neuropathological diagnosis of AD (B2 tau pathology in the presence of at least moderate levels of cortical amyloid pathology) in patients
with a negative TAUVID scan. Consider additional evaluation to confirm the absence of AD pathology in patients with a negative TAUVID scan.
False Positive TAUVID Scan
Small foci of noncontiguous tracer uptake may lead to a false positive TAUVID scan. Only uptake of tracer in the neocortex should contribute to the interpretation
of a positive TAUVID scan.
Risk of Chronic Traumatic Encephalopathy Misdiagnosis
The safety and effectiveness of TAUVID have not been established for patients being evaluated for CTE. Preliminary non-clinical and clinical investigations
suggest differences in tau conformation and distribution may limit flortaucipir F 18 binding. Therefore, TAUVID is not indicated for detection of CTE.
Radiation Risk
Diagnostic radiopharmaceuticals, including TAUVID, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer.
Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure.
ADVERSE REACTIONS
The most common adverse reactions reported in clinical trials were headache (1.4%), injection site pain (1.2%), and increased blood pressure (0.8%).
USE IN SPECIFIC POPULATIONSPregnancyAll radiopharmaceuticals, including TAUVID, have the potential to cause fetal harm depending on the fetal stage of development
and the magnitude radiation dose. Advise a pregnant woman of the potential risks of fetal exposure to radiation doses with administration of TAUVID.
LactationAdvise a lactating woman to avoid breastfeeding for 4 hours after TAUVID administration in order to minimize radiation exposure to a breastfed infant.
Please see Full Prescribing Information for TAUVID.
FT HCP ISI 14SEP2022
Indication
TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD).
Limitations of Use
TAUVID is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).
- TAUVID for intravenous use is supplied in multidose vials containing 300-3700 Mbq/mL flortaucipir F 18.